SUN Pharma ANZ Pty Limited Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: SUN Pharma ANZ Pty Limited Pharmaceutical Import Records from India — 11 Products, $34.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SUN Pharma ANZ Pty Limited — Pharmaceutical Importer Profile (2026) | 11 Products, $34.8M Trade | TransData Nexus

SUN Pharma ANZ Pty Limited

Pharmaceutical Importer · Australia · Gastrointestinal Focus · $34.8M Total Trade · DGFT Verified

SUN Pharma ANZ Pty Limited is a pharmaceutical importer based in Australia with a total trade value of $34.8M across 11 products in 7 therapeutic categories. Based on 861 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. SUN Pharma ANZ Pty Limited sources from 1 verified Indian supplier, with Sun Pharmaceutical Industries Limited accounting for 100.0% of imports.

SUN Pharma ANZ Pty Limited — Import Portfolio & Supplier Network

SUN Pharma ANZ Pty Limited import network — 11 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to SUN Pharma ANZ Pty Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$11.6M	431	100.0%

SUN Pharma ANZ Pty Limited sources from 1 verified Indian supplier across 309 distinct formulations. The sourcing is highly concentrated — Sun Pharmaceutical Industries Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Atorvastatin sz 80MG Each film coated tablet contains:atorvastatin calcium eq toatorvastatin 80 MG Pack : box3x10s	$229.1K	7
Ganirelix sun 250 microgram/0.5 ML	$200.0K	4
Esomeprazole magnesium gastro resistanttablets 20 MG (apo-esomeprazole TAB 20MG(cfb) aust) Each gastroresistant	$150.7K	6
Mesalamine delayed release tablets USP	$150.0K	3
Liposo ampho INJ 50MG/vial 1s vial aus/ liposomal amphotericin b amphotericin powder for injection 50	$150.0K	3
Entecavir tablets 0.5 MG Each f/c tabletcontains: entecavir monohydrate equivalent to entecavir 0.5 MG. Pack:box3x10s	$143.4K	3
Esomeprazole magnesium gastro resistanttablets 20 MG (apo-esomeprazole TAB 20MG(cfb) aust) Each gastroresistant	$140.1K	3
Apo atorvastatin TAB 40 MG: Each film coated tablet contains: atorvastatin calcium eq to atorvastatin 40 MG Pack	$117.6K	4
Meropenem ranbaxy 1GM Each vial	$100.0K	2
Levothyroxine sodium tablets 50 MCG	$100.0K	2
Esomeprazole magnesium gastro resistanttablets 20 MG (guardium acid rr TAB 20mg2x7b(cfb)aust) Each Gastro-Resistant	$100.0K	2
Atorvastatin sz 40MG Each film coated tablet contains: atorvastatin calcium eqto atorvastatin 40 MG Pack : box3x10s	$100.0K	2
Levothyroxine sodium tablets 100 MCG	$100.0K	2
Atorvastatin sz 80MG Each film coated tablet contains:atorvastatin calcium eq toatorvastatin 80 MG Pack : box3x10s	$100.0K	2
Valaciclovir rbx tablets 500MG valaciclovir rbx 500mgeach film coated tablet contains:valaciclovir	$100.0K	2

Import Portfolio — Top 11 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Esomeprazole	Gastrointestinal	$10.8M	278	1.7%	9
2	Magnesium	Vitamins & Supplements	$10.7M	275	2.2%	7
3	Omeprazole	Gastrointestinal	$5.0M	120	0.8%	17
4	Levothyroxine	Diabetes & Endocrine	$4.9M	121	4.5%	5
5	Amphotericin	Antifungals	$600.0K	12	0.4%	7
6	Sunitinib	Advanced Oncology	$600.0K	12	0.7%	7
7	Dasatinib	Advanced Oncology	$550.0K	11	0.9%	7
8	Mesalamine	Gastrointestinal	$550.0K	11	0.0%	14
9	Imatinib	Advanced Oncology	$400.0K	8	0.3%	11
10	Doxorubicin	Oncology	$350.0K	7	0.5%	10
11	Tobramycin	Antibiotics	$300.0K	6	0.8%	16

SUN Pharma ANZ Pty Limited imports 11 pharmaceutical products across 7 categories into Australia totaling $34.8M.

SUN Pharma ANZ Pty Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sun Pharma ANZ Pty Limited is an Australian proprietary company specializing in the importation and distribution of pharmaceutical products. Established on September 8, 2004, the company is headquartered in Macquarie Park, New South Wales, Australia. It operates as a subsidiary of Sun Pharmaceutical Industries Limited, a leading global specialty generic pharmaceutical company based in Mumbai, India. Sun Pharma ANZ plays a pivotal role in Australia's pharmaceutical supply chain by sourcing and supplying a diverse range of finished pharmaceutical formulations to meet the country's healthcare needs.

2Distribution Network

While specific details about Sun Pharma ANZ's warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Macquarie Park, New South Wales, suggests a well-established distribution network. This location provides efficient access to major transportation routes, facilitating timely delivery of pharmaceutical products across Australia. The company's extensive import activities, including 861 shipments from India, indicate a robust logistics framework capable of managing a diverse product portfolio.

3Industry Role

Sun Pharma ANZ Pty Limited functions primarily as a pharmaceutical importer and distributor within Australia's healthcare sector. By sourcing finished pharmaceutical formulations from India, the company ensures a steady supply of essential medications to the Australian market. Its role is crucial in bridging the gap between international pharmaceutical manufacturers and local healthcare providers, thereby contributing to the availability and accessibility of a wide range of therapeutic products.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — SUN Pharma ANZ Pty Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sun Pharma ANZ's sourcing strategy exhibits a high degree of concentration, with 100% of its pharmaceutical imports originating from Sun Pharmaceutical Industries Limited in India. This exclusive partnership underscores a strategic choice to maintain a consistent supply of quality products. The substantial volume of imports—totaling $34.8 million USD across 861 shipments—reflects a stable and dependable relationship between Sun Pharma ANZ and its sole supplier. However, this single-source dependency also presents potential risks, such as supply chain disruptions due to geopolitical issues or manufacturing challenges in India. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

2Supply Chain Resilience

The resilience of Sun Pharma ANZ's supply chain is closely tied to the stability and reliability of Sun Pharmaceutical Industries Limited in India. Given the exclusive nature of their partnership, any disruptions in India's manufacturing capabilities or regulatory changes could significantly impact Sun Pharma ANZ's operations. The company's import data indicates a diverse range of 309 unique formulations, suggesting a broad product portfolio. However, the lack of publicly available information on backup suppliers and alternative sourcing strategies highlights a potential vulnerability. To bolster supply chain resilience, it would be prudent for Sun Pharma ANZ to explore additional supplier relationships and ensure compliance with Australian regulatory standards.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the Therapeutic Goods Administration (TGA) is the primary regulatory body responsible for overseeing the safety, efficacy, and quality of therapeutic goods, including pharmaceuticals. The TGA operates under the Therapeutic Goods Administration Act 1989, which provides the legislative framework for regulating therapeutic goods in Australia. This act outlines the requirements for the registration, importation, and supply of medicines, ensuring that all therapeutic goods meet stringent standards before they are made available to the Australian public. (tga.gov.au)

2Import Licensing & GMP

To import therapeutic goods into Australia, companies must comply with the Therapeutic Goods Administration Act 1989, which requires that all medicines be entered in the Australian Register of Therapeutic Goods (ARTG) before they can be legally imported. This process ensures that imported medicines meet Australian standards for safety, efficacy, and quality. Additionally, the TGA mandates that all medicines be manufactured in accordance with Good Manufacturing Practice (GMP) regulations. These standards ensure that therapeutic goods are consistently produced and controlled to quality standards appropriate to their intended use. (tga.gov.au)

Quality & Labeling

SUN Pharma ANZ Pty Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sun Pharma ANZ Pty Limited's focus on importing pharmaceutical products across therapeutic categories such as gastrointestinal, vitamins & supplements, and diabetes & endocrine reflects a strategic alignment with prevalent health concerns in Australia. The substantial import values in these categories indicate a strong market demand for these products. By concentrating on these therapeutic areas, Sun Pharma ANZ addresses critical healthcare needs, ensuring the availability of essential medications to the Australian population.

2Sourcing Profile

Sun Pharma ANZ's sourcing strategy is centered on importing finished pharmaceutical formulations from Sun Pharmaceutical Industries Limited in India. This approach allows the company to offer a diverse range of products, including generics and specialty medications, across various therapeutic areas. By leveraging India's manufacturing capabilities, Sun Pharma ANZ can provide cost-effective solutions while maintaining product quality. This strategy aligns with the company's commitment to improving access to medicines in Australia.

3Market Positioning

Based on its product mix, Sun Pharma ANZ Pty Limited serves multiple segments of the Australian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's diverse product portfolio enables it to meet the needs of various healthcare providers and consumers, positioning it as a versatile and reliable supplier in the Australian market.

Seller's Guide — How to Become a Supplier to SUN Pharma ANZ Pty Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Australian market by offering alternative products or formulations that meet TGA standards. Given Sun Pharma ANZ's concentrated sourcing strategy, introducing complementary products could help diversify its portfolio and reduce dependency on a single supplier. Identifying gaps in Sun Pharma ANZ's current sourcing, such as unmet therapeutic needs or emerging health trends, presents avenues for new suppliers to establish partnerships and expand their market presence in Australia.

2Requirements & Qualifications

Indian exporters seeking to supply Sun Pharma ANZ Pty Limited and the Australian market must ensure that their products are registered in the ARTG and manufactured in compliance with TGA's GMP standards. Additionally, products must meet Australian labeling requirements, including English language labeling and necessary product information. Exporters should also be prepared to provide evidence of quality control measures and product testing to demonstrate compliance with Australian regulations. (tga.gov.au)

3How to Approach

Frequently Asked Questions — SUN Pharma ANZ Pty Limited

What products does SUN Pharma ANZ Pty Limited import from India?

SUN Pharma ANZ Pty Limited imports 11 pharmaceutical products across 7 categories. Top imports: Esomeprazole ($10.8M), Magnesium ($10.7M), Omeprazole ($5.0M), Levothyroxine ($4.9M), Amphotericin ($600.0K).

Who supplies pharmaceuticals to SUN Pharma ANZ Pty Limited from India?

SUN Pharma ANZ Pty Limited sources from 1 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (100.0% of imports, $11.6M).

What is SUN Pharma ANZ Pty Limited's total pharmaceutical import value?

SUN Pharma ANZ Pty Limited's total pharmaceutical import value from India is $34.8M, based on 861 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does SUN Pharma ANZ Pty Limited focus on?

SUN Pharma ANZ Pty Limited imports across 7 categories. The largest: Gastrointestinal (47.0%), Vitamins & Supplements (30.7%), Diabetes & Endocrine (14.2%).

Get Full SUN Pharma ANZ Pty Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.